CA2038945A1 - Liberation locale de peptides/proteines incluses dans des liposomes obtenus par deshydratation/rehydratation - Google Patents

Liberation locale de peptides/proteines incluses dans des liposomes obtenus par deshydratation/rehydratation

Info

Publication number
CA2038945A1
CA2038945A1 CA 2038945 CA2038945A CA2038945A1 CA 2038945 A1 CA2038945 A1 CA 2038945A1 CA 2038945 CA2038945 CA 2038945 CA 2038945 A CA2038945 A CA 2038945A CA 2038945 A1 CA2038945 A1 CA 2038945A1
Authority
CA
Canada
Prior art keywords
liposomes
interferon
peptide
composition
skin
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA 2038945
Other languages
English (en)
Inventor
Norman D. Weiner
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Michigan
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2038945A1 publication Critical patent/CA2038945A1/fr
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1277—Processes for preparing; Proliposomes
    • A61K9/1278—Post-loading, e.g. by ion or pH gradient

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Dispersion Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CA 2038945 1989-08-01 1990-08-01 Liberation locale de peptides/proteines incluses dans des liposomes obtenus par deshydratation/rehydratation Abandoned CA2038945A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US38791589A 1989-08-01 1989-08-01
US387,915 1989-08-01

Publications (1)

Publication Number Publication Date
CA2038945A1 true CA2038945A1 (fr) 1991-02-02

Family

ID=23531834

Family Applications (1)

Application Number Title Priority Date Filing Date
CA 2038945 Abandoned CA2038945A1 (fr) 1989-08-01 1990-08-01 Liberation locale de peptides/proteines incluses dans des liposomes obtenus par deshydratation/rehydratation

Country Status (4)

Country Link
EP (1) EP0437577A1 (fr)
JP (1) JPH04501123A (fr)
CA (1) CA2038945A1 (fr)
WO (1) WO1991001719A1 (fr)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4121388A1 (de) * 1991-02-07 1992-08-13 Nattermann A & Cie Pharmazeutisches produkt zur behandlung von viruserkrankungen
DE4121389A1 (de) * 1991-02-07 1992-08-13 Nattermann A & Cie Pharmazeutisches produkt zur behandlung von viruserkrankungen
WO1993004672A1 (fr) * 1991-09-11 1993-03-18 Pitman-Moore, Inc. Procede de renforcement du systeme immunitaire d'un hote a l'aide de polypeptides encapsules dans des liposomes
US6372249B1 (en) 1991-12-16 2002-04-16 Baylor College Of Medicine Senscent cell-derived inhibitors of DNA synthesis
US5853755A (en) * 1993-07-28 1998-12-29 Pharmaderm Laboratories Ltd. Biphasic multilamellar lipid vesicles
ATE195866T1 (de) * 1993-07-28 2000-09-15 Pharmaderm Lab Ltd Zweiphasige multilamellare lipidvesikel
FR2725130B1 (fr) * 1994-09-29 1996-10-31 Oreal Compositions cosmetiques contenant un compose lipidique de type ceramide et un peptide a une chaine grasse, et leurs utilisations
RU2103006C1 (ru) * 1995-03-23 1998-01-27 Олег Викторович Травкин Иммуномодулирующее лекарственное средство
US6197743B1 (en) 1996-07-26 2001-03-06 The Trustees Of Boston University Compositions and methods for the treatment of viral disorders
EP2298350A3 (fr) * 1996-07-26 2011-06-08 Susan P. Perrine Compositions contenant un agent inducteur ainsi qu'un agent antiviral et destinees au traitement de troubles viraux
KR100190826B1 (ko) * 1996-08-26 1999-06-01 강재헌 적혈구 용혈 억제용 약제학적 조성물 및 그의제조방법
AU774861B2 (en) 1998-02-11 2004-07-08 Douglas V Faller Compositions and methods for the treatment of cystic fibrosis
HK1077740A1 (en) 2001-12-20 2006-02-24 Ct Ingenieria Genetica Biotech Use of epidermal growth factor in the manufacture of a pharmaceutical injection composition for preventing diabetic limb amputation
FR2880627B1 (fr) * 2005-01-07 2007-05-18 Silab Sa Procede d'obtention d'un principe actif pour l'eclat du teint, principe actif obtenu et compositions associees
US7727537B2 (en) 2005-02-14 2010-06-01 Dpm Therapeutics Corp. Stabilized compositions for topical administration and methods of making same
US7838011B2 (en) 2005-02-14 2010-11-23 Pankaj Modi Stabilized protein compositions for topical administration and methods of making same
PT1853303E (pt) * 2005-02-14 2016-03-23 Dpm Therapeutics Corp Composições estabilizadas para administração tópica, e métodos para a sua preparação
CU23411B6 (es) * 2005-12-29 2009-09-08 Ct Ingenieria Genetica Biotech Uso tópico del factor de crecimiento epidérmico en liposomas para prevenir la amputación del pie diabético
CU23388B6 (es) 2006-01-31 2009-07-16 Ct Ingenieria Genetica Biotech Composición farmacéutica de microesferas para prevenir la amputación del pie diabético
CA2730952C (fr) * 2008-08-04 2016-07-19 Dr. Suwelack Skin & Health Care Ag Composition contenant du sulfate de cholesteryle en tant qu'agent hemostatique
US20110086869A1 (en) 2009-09-24 2011-04-14 The Trustees Of Boston University Methods for treating viral disorders
CN102802412A (zh) 2009-12-08 2012-11-28 海玛奎斯特医药公司 用于治疗红细胞病症的方法及低剂量方案
US20110245154A1 (en) 2010-03-11 2011-10-06 Hemaquest Pharmaceuticals, Inc. Methods and Compositions for Treating Viral or Virally-Induced Conditions
KR20220034736A (ko) 2019-05-31 2022-03-18 비락타 서브시디어리 인크. 히스톤 데아세틸라제 억제제를 사용하여 바이러스 관련 암을 치료하는 방법

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3301951A1 (de) * 1983-01-21 1984-07-26 A. Nattermann & Cie GmbH, 5000 Köln Liposome mit einem gehalt eines sperma-antigen-peptids
US4515736A (en) * 1983-05-12 1985-05-07 The Regents Of The University Of California Method for encapsulating materials into liposomes
DE3582905D1 (de) * 1984-08-10 1991-06-27 Syntex Inc Stabile liposome mit wasserloeslichen arzneimitteln.
WO1989005151A1 (fr) * 1987-12-04 1989-06-15 The Liposome Company, Inc. Liposomes a degre de stabilite eleve et procede de preparation et d'utilisation de tels liposomes

Also Published As

Publication number Publication date
EP0437577A1 (fr) 1991-07-24
WO1991001719A1 (fr) 1991-02-21
JPH04501123A (ja) 1992-02-27

Similar Documents

Publication Publication Date Title
CA2038945A1 (fr) Liberation locale de peptides/proteines incluses dans des liposomes obtenus par deshydratation/rehydratation
Weiner et al. Topical delivery of liposomally encapsulated interferon evaluated in a cutaneous herpes guinea pig model
US6153217A (en) Nanocochleate formulations, process of preparation and method of delivery of pharmaceutical agents
EP0267050B1 (fr) Aérosols contenant des liposomes et méthods pour leur production.
US4844904A (en) Liposome composition
US5049388A (en) Small particle aerosol liposome and liposome-drug combinations for medical use
Hashimoto et al. Depletion of alveolar macrophages decreases neutrophil chemotaxis to Pseudomonas airspace infections
US5200393A (en) Lipid excipient for nasal delivery and topical application
US6544542B1 (en) Fat emulsions for inhalational administration
Düzgüneş et al. Enhanced effect of liposome-encapsulated amikacin on Mycobacterium avium-M. intracellulare complex infection in beige mice
Egbaria et al. Topical delivery of liposomally encapsulated interferon evaluated by in vitro diffusion studies
du Plessis et al. Topical delivery of liposomally encapsulated gamma-interferon
EP0963196B1 (fr) Systeme hyaluronique d'administration de medicaments
WO1990014074A1 (fr) Formulations liposomiques ameliorees de nucleotides et d'analogues de nucleotides
Singh et al. Preparation and in vitro, in vivo characterization of elastic liposomes encapsulating cyclodextrin-colchicine complexes for topical delivery of colchicine
Jain et al. PEGylated elastic liposomal formulation for lymphatic targeting of zidovudine
US6656499B1 (en) Composition for transdermal and dermal administration of interferon-α
EP1265638A1 (fr) Compositions pour administration transdermique et transmuqueuse d'agents therapeutiques
US6117857A (en) Pharmaceutical composition
Sharma et al. A Review on Novel Vesicular Drug Delivery System: Transfersomes.
Bergers et al. Interleukin-2-containing liposomes: interaction of interleukin-2 with liposomal bilayers and preliminary studies on application in cancer vaccines
EPPSTEIN Altered pharmacologic properties of liposome-associated human interferon-alpha. II.
Goldbach et al. In situ activation of mouse alveolar macrophages by aerosolized liposomal IFN-gamma and muramyl tripeptide
Weiner et al. Topical delivery of liposomally encapsulated interferon evaluated by in vitro diffusion studies and in a cutaneous herpes Guinea pig model
WO1991006310A1 (fr) Compositions liposomiques

Legal Events

Date Code Title Description
FZDE Dead